Cure8 research brief
A blood biomarker that tracks both symptoms and endoscopic inflammation could help with noninvasive monitoring of ulcerative colitis activity and reduce reliance on invasive procedures if validated.
Clinicians and researchers studying UC biomarkers; adult patients interested in advances in noninvasive disease monitoring.
This was a prospective, single-center case–control study comparing 105 patients with UC to 68 healthy controls. Serum sENG was measured by ELISA and showed higher median values in UC versus controls, and moderate-to-strong correlations with partial Mayo clinical scores and Mayo endoscopic subscores.
The authors also report correlations between sENG and inflammatory cytokines (IL-6, TNF-α, IFN-γ, IL-17A). The paper presents diagnostic-performance metrics (AUCs) and reports that higher sENG remained independently associated with clinically active disease after multivariable adjustment.
The authors note that external validation and direct comparison with established biomarkers are needed before clinical use.
The source is a single-center clinical study reported in a journal abstract; findings require external validation and head-to-head comparison with established biomarkers before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...
